T80.A19A Non-ABO incompatibility with hemolytic transfusion reaction, unspecified, initial encounter

Name of the Condition

• Non-ABO incompatibility with hemolytic transfusion reaction, unspecified, initial encounter.

Summary

This condition describes an adverse reaction resulting from the transfusion of blood or blood products that is not due to ABO blood group incompatibility, specifically involving hemolysis. It occurs when the recipient’s immune system reacts to non-ABO antigens in the transfused material, leading to the destruction of red blood cells and associated clinical manifestations. The term "unspecified" indicates the reaction type is not further classified, and "initial encounter" denotes the first episode of care for this condition.

Causes

Non-ABO incompatibility with hemolytic transfusion reactions can arise from immune responses to minor blood group antigens, such as Rh, Kell, Duffy, or Kidd systems, or antibodies against platelet or plasma proteins. These reactions may be triggered by prior sensitization through pregnancy, previous transfusions, or organ transplants, where the recipient has developed antibodies against these antigens.

Risk Factors

• Prior exposure to incompatible blood products
• History of multiple transfusions or pregnancies
• Underlying immune-mediated conditions
• Use of blood products with non-ABO antigen mismatches
• Lack of pre-transfusion antibody screening in high-risk patients

Symptoms

• Fever, chills, or rigors
• Skin reactions (rash, urticaria, or flushing)
• Respiratory distress (wheezing, shortness of breath)
• Hypotension or tachycardia
• Hemolysis (evidenced by dark urine or jaundice)

Diagnosis

Diagnosis involves clinical evaluation of transfusion reaction symptoms, laboratory testing to confirm hemolysis (e.g., elevated bilirubin, decreased haptoglobin, hemoglobinuria), and antibody screening to identify non-ABO antigen incompatibility. Crossmatching and direct antiglobulin testing may be used to detect immune-mediated red blood cell destruction.

Treatment Options

Management focuses on discontinuing the transfusion, providing supportive care (e.g., fluids, oxygen), and treating hemolysis or associated complications. Specific interventions may include corticosteroids, antihistamines, or renal support for severe cases. Transfusion of compatible blood products is essential for ongoing care.

Prognosis and Follow-Up

Prognosis depends on the severity of the reaction and promptness of treatment. Most mild cases resolve with supportive care, while severe reactions may lead to organ damage or death. Follow-up includes monitoring for delayed complications and ensuring future transfusions use compatible blood products.

Complications

• Acute kidney injury from hemoglobinuria
• Disseminated intravascular coagulation (DIC)
• Shock or multi-organ failure
• Death (in severe cases)

Lifestyle & Prevention

Prevention involves thorough pre-transfusion antibody screening, using leukoreduced or washed blood products, and adhering to strict crossmatching protocols. Patients with a history of sensitization should receive antigen-negative blood to minimize risk.

When to Seek Professional Help

Seek immediate medical attention if symptoms of a transfusion reaction occur during or after a blood transfusion, including fever, chills, shortness of breath, or dark urine. Prompt evaluation is critical to prevent severe complications.

Tips for Medical Coders

Document the encounter as the initial episode of care for a non-ABO incompatibility with hemolytic transfusion reaction. Ensure clinical notes specify the reaction is unspecified (not acute or delayed) and confirm the initial encounter status. Code T80.A19A is appropriate when the reaction type is not further classified and this is the first episode of care.